Immunology
The complete molecular and cellular biology of the immune system — innate and adaptive immunity, B and T lymphocyte development and activation, antibody classes and function, MHC and antigen presentation, complement, cytokines, tolerance, autoimmunity, hypersensitivity, vaccines, and primary and secondary immunodeficiency.
The immune system is simultaneously one of the most complex and one of the most consequential biological systems in the human body. Its task — to distinguish self from non-self, to identify and eliminate pathogens without destroying healthy tissue, and to remember past encounters so that subsequent responses are faster and more effective — requires a degree of molecular discrimination that surpasses any human-engineered recognition system. Understanding immunology is not simply memorising cell types and antibody classes; it is understanding the logic of immune recognition, the regulatory mechanisms that prevent catastrophic self-attack, and the consequences when those mechanisms fail. These principles underpin medicine across disciplines — from infectious disease and vaccine development to oncology, transplantation, allergy, and rheumatology.
The Immune System: Architecture, Layered Defence, and the Logic of Self/Non-Self Discrimination
The immune system is not a single organ but a distributed network of cells, tissues, proteins, and molecular signals distributed throughout the body. Its primary lymphoid organs — bone marrow and thymus — are the sites of lymphocyte development and maturation. Its secondary lymphoid organs — lymph nodes, spleen, tonsils, Peyer’s patches, and mucosa-associated lymphoid tissue (MALT) — are the sites where adaptive immune responses are initiated through encounters between antigen-presenting cells and naïve lymphocytes. Circulating blood and lymph carry immune cells between tissues, enabling rapid mobilisation of immune resources to sites of infection or injury.
The immune system is organised around a fundamental conceptual problem: how to identify and eliminate an essentially unlimited diversity of potential pathogens without attacking the trillions of self-cells that make up the host. Two complementary recognition strategies address different aspects of this problem. The innate immune system uses germline-encoded receptors that recognise conserved structural features shared by broad classes of pathogens — pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide, peptidoglycan, flagellin, and viral dsRNA — that are absent from (or rare in) host cells. The adaptive immune system generates, through somatic gene rearrangement, an enormous diversity of antigen-specific receptors that can in principle recognise any molecular structure — self or non-self — and relies on tolerance mechanisms to ensure self-reactive clones are eliminated or silenced.
Innate Immunity: Physical Barriers, Pattern Recognition, and Immediate Defence
Innate immunity comprises the body’s first-line defences — physical and chemical barriers that prevent pathogen entry, and rapid cellular and molecular responses activated immediately upon breach of those barriers. It is non-specific, lacks immunological memory, and responds with essentially the same intensity regardless of how many times the same pathogen is encountered. Its value lies in its speed: innate immune activation occurs within minutes to hours, containing most infections long enough for the adaptive immune response to develop.
Physical and Chemical Barriers
Skin keratinocytes form a physical barrier; mucus traps microorganisms; cilia sweep them away; acidic stomach pH destroys ingested pathogens; antimicrobial peptides (defensins, lysozyme, lactoferrin) disrupt microbial membranes; the commensal microbiome competes with pathogens for niche and nutrients.
Pattern Recognition Receptors
Germline-encoded PRRs detect PAMPs. Toll-like receptors (TLRs 1–13) recognise bacterial lipoproteins, LPS, flagellin, and viral nucleic acids. NOD-like receptors detect intracellular PAMPs. RIG-I/MDA5 detect cytoplasmic dsRNA. cGAS-STING pathway detects cytoplasmic DNA. NLRP3 inflammasome detects danger signals and activates IL-1β.
Inflammation — the Innate Effector Response
PRR activation triggers inflammation through NF-κB and IRF transcription factors: prostaglandins, leukotrienes, and cytokines increase vascular permeability; selectins and integrins mediate neutrophil rolling and extravasation; complement fragments and chemokines direct phagocyte recruitment to the site of infection.
Toll-Like Receptors — The Molecular Sensors of the Innate Immune System
Toll-like receptors are the best-characterised pattern recognition receptor family and serve as a primary link between pathogen detection and innate immune activation. Each TLR recognises a specific class of PAMP: TLR4 detects lipopolysaccharide (LPS) from Gram-negative bacteria — with the co-receptors MD-2 and CD14 forming the LPS recognition complex; TLR3 detects double-stranded RNA (produced during viral replication); TLR7 and TLR8 detect single-stranded RNA (viral genomes); TLR9 detects unmethylated CpG dinucleotides in bacterial and viral DNA. TLR signalling proceeds through adaptor proteins — MyD88 (used by most TLRs), TRIF (used by TLR3 and TLR4), TRAM, and TIRAP — activating NF-κB (producing pro-inflammatory cytokines) and IRF3/IRF7 (producing type I interferons). Type I interferons (IFN-α and IFN-β) are the primary antiviral innate effectors — they induce an antiviral state in surrounding cells, upregulate MHC class I expression (increasing antigen presentation to cytotoxic T cells), and activate NK cells.
In addition to PAMPs from pathogens, innate immune receptors also detect damage-associated molecular patterns (DAMPs) — endogenous molecules released by damaged or dying host cells that normally reside inside cells or are structurally modified by cellular stress. DAMPs include HMGB1 (a nuclear protein released from necrotic cells), ATP (released by dying cells, sensed by P2X7 receptor), uric acid crystals, heat shock proteins, and mitochondrial DNA. DAMP signalling activates the NLRP3 inflammasome and NF-κB through the same PRR pathways as PAMPs, producing sterile inflammation — inflammation in the absence of infection — relevant to ischaemia-reperfusion injury, gout, atherosclerosis, and trauma. The cGAS-STING pathway detects cytoplasmic double-stranded DNA from damaged mitochondria or nuclear DNA — an important mediator of inflammatory signalling in autoimmune conditions including systemic lupus erythematosus and Aicardi-Goutières syndrome.
Innate Immune Cells: Neutrophils, Macrophages, NK Cells, and Dendritic Cells
The cellular arm of innate immunity comprises several distinct cell types with complementary functions — phagocytes that ingest and destroy pathogens, innate lymphocytes that kill infected cells without prior antigen sensitisation, and antigen-presenting cells that bridge innate and adaptive immunity by processing and displaying pathogen-derived antigens to T cells.
Neutrophils
First responders; most abundant circulating leukocyte. Phagocytose and destroy bacteria via oxidative burst (NADPH oxidase → superoxide → HOCl) and granule proteins (elastase, myeloperoxidase). Form NETs (Neutrophil Extracellular Traps). Short-lived (~12h in blood).
Macrophages
Tissue-resident phagocytes (Kupffer cells, alveolar macrophages, microglia). Engulf pathogens via Fc and complement receptors. Secrete pro-inflammatory cytokines (TNF, IL-1β, IL-6, IL-12). M1 (classical activation, microbicidal) vs M2 (alternative, tissue repair) polarisation.
Dendritic Cells
Professional antigen-presenting cells bridging innate and adaptive immunity. Sample antigens, migrate to lymph nodes, present peptide-MHC to naïve T cells, provide co-stimulatory signals (CD80/86) and cytokines directing T cell differentiation. Plasmacytoid DCs are primary IFN-α producers.
NK Cells
Innate lymphocytes that kill virus-infected and tumour cells without prior sensitisation. Use ‘missing-self’ recognition — attack cells with reduced MHC class I (a common viral immune evasion strategy). Activating receptors (NKG2D, NCRs) detect stress ligands on target cells. Kill via perforin/granzyme or ADCC.
Mast Cells
Tissue-resident cells loaded with IgE bound via FcεRI. Cross-linking by allergen triggers degranulation: histamine, proteases, prostaglandins, leukotrienes. Drive Type I hypersensitivity. Also contribute to anti-parasitic immunity and wound healing through cytokine secretion.
Basophils
Circulating counterparts to mast cells; also express FcεRI and contribute to IgE-mediated reactions. Rare in blood (<1%) but amplify allergic and anti-helminth responses through IL-4 and IL-13 secretion after activation. Also present at sites of delayed-type hypersensitivity.
Eosinophils
Specialised in anti-parasitic defence; release toxic granule proteins (major basic protein, eosinophil cationic protein) onto large targets too big to phagocytose. Recruited by IL-5 in allergic inflammation and helminth infection. Elevated in allergy and parasitic disease (eosinophilia).
ILCs
Innate Lymphoid Cells — innate counterparts to adaptive T helper subsets. ILC1 (IFN-γ, anti-intracellular); ILC2 (IL-4/IL-5/IL-13, anti-helminth, allergy); ILC3 (IL-17/IL-22, gut barrier, anti-extracellular bacteria). Respond to cytokines rather than specific antigens via rearranged receptors.
The Complement System: Three Activation Pathways and Their Convergence on C3
The complement system is a proteolytic cascade of approximately 30 plasma and membrane-associated proteins that, when activated, produce effectors capable of directly destroying pathogens, opsonising them for phagocytosis, recruiting inflammatory cells, and enhancing adaptive immune responses. It forms a critical bridge between innate pattern recognition and the effector mechanisms that clear pathogens, and is the mechanism by which antibodies achieve many of their anti-microbial functions.
Classical Pathway — Antibody-Initiated Complement Activation
Initiated when C1q (part of the C1 complex, also containing C1r and C1s proteases) binds to the Fc regions of IgG or IgM antibodies that are themselves bound to antigen — requiring at least two IgG molecules in proximity, or one pentameric IgM molecule, to achieve C1q binding. C1q binding causes conformational changes activating C1r, which cleaves and activates C1s. C1s cleaves C4 (→ C4a + C4b) and C2 (→ C2a + C2b), assembling the C3 convertase C4b2a. This pathway links antibody-mediated recognition (adaptive immunity) to complement effector mechanisms — explaining why IgG and IgM antibodies are particularly effective at clearing bacterial infections through complement-mediated lysis.
Lectin Pathway — Carbohydrate Pattern Recognition
Mannose-binding lectin (MBL) and ficolins are pattern recognition molecules that bind carbohydrate structures on pathogen surfaces (mannose-rich polysaccharides, N-acetylglucosamine). Unlike C1q, they do not require antibody — they detect PAMPs directly. MBL and ficolins are structurally homologous to C1q and associate with their own serine proteases (MASP-1 and MASP-2), which cleave C4 and C2 to generate the same C3 convertase (C4b2a) as the classical pathway. The lectin pathway provides rapid, antibody-independent complement activation against many common bacterial pathogens in the early phase of infection, before specific antibodies have been generated — an important innate immune contribution.
Alternative Pathway — Constitutive Activation and Amplification
The alternative pathway operates through spontaneous, low-level hydrolysis of C3 in plasma (“C3 tick-over”), producing C3(H₂O) that can form a fluid-phase C3 convertase with factors B and D. On most host cell surfaces, regulatory proteins (Factor H, CD55) rapidly inactivate this nascent convertase. On pathogen surfaces — which lack these regulators — the convertase is stabilised by properdin and generates C3b, which deposits on the surface, recruits more Factor B and D, and amplifies the complement response. The alternative pathway therefore acts as a self-amplification loop: a small amount of C3b generated by any pathway is amplified by the alternative pathway, accelerating complement deposition on pathogen surfaces while host cells remain protected by surface regulators.
Terminal Pathway and the Membrane Attack Complex (MAC)
All three activation pathways converge on cleavage of C3 into C3a and C3b. C3b deposited on the pathogen surface creates the C5 convertase (by associating with C4b2a or factor Bb), which cleaves C5 into C5a and C5b. C5a is a potent anaphylatoxin and chemotactic factor — one of the most powerful pro-inflammatory mediators in biology. C5b initiates the terminal pathway: sequential binding of C6, C7, C8, and multiple C9 molecules assembles the Membrane Attack Complex (MAC) — a pore in the bacterial membrane that disrupts osmotic homeostasis and causes lysis. MAC-mediated lysis is particularly critical against Neisseria species (meningococcus, gonococcus); individuals with terminal complement deficiencies (C5–C9) are specifically susceptible to meningococcal disease.
Adaptive Immunity: Lymphocyte Development, Antigen Specificity, and Immunological Memory
Adaptive immunity is the antigen-specific arm of the immune response — characterised by clonal selection of lymphocytes with the appropriate specificity, expansion of those selected clones, generation of effector cells that eliminate the pathogen, and production of long-lived memory cells that enable a faster and stronger response upon re-exposure. It is mediated by two principal cell types: B lymphocytes (responsible for antibody-mediated humoral immunity) and T lymphocytes (responsible for cell-mediated immunity and helper functions for B cells).
Lymphocyte Development and the Generation of Receptor Diversity
Both B and T cells originate from common lymphoid progenitors in the bone marrow. B cells complete their development in the bone marrow; T cell progenitors migrate to the thymus where they undergo T cell-specific development. In both cases, the defining developmental event is the somatic recombination of antigen receptor gene segments to generate a unique receptor with a randomly generated antigen-binding site — a process called V(D)J recombination, catalysed by the RAG1 and RAG2 recombinases that bring together Variable (V), Diversity (D), and Joining (J) gene segments from large arrays of germline-encoded options.
The combinatorial diversity from V(D)J recombination is staggering: ~10⁶ possible heavy chain rearrangements × ~10³ possible light chain rearrangements = ~10⁹ unique immunoglobulin specificities before junctional diversity (random nucleotide additions and deletions at the V-D and D-J junctions) increases this to an estimated 10¹⁶. T cell receptor diversity is generated by the same mechanism. The sheer enormity of this repertoire — generated before any antigen encounter — is the molecular basis for the immune system’s ability to recognise essentially any molecular structure.
Following receptor assembly, developing lymphocytes undergo selection for appropriate antigen-binding properties. In the thymus, T cells undergo positive selection (survival of cells whose TCR can interact with self-MHC, ensuring MHC restriction) and negative selection (deletion of cells with high affinity for self-peptide/MHC complexes, central tolerance). In the bone marrow, B cells with BCRs that bind self-antigens too strongly undergo receptor editing (BCR rearrangement to a new specificity) or are deleted; those that bind too weakly fail to receive survival signals and die. The result is a peripheral lymphocyte repertoire that is MHC-restricted (for T cells), capable of recognising foreign antigens, and broadly tolerant of self.
MHC Molecules and Antigen Presentation: Teaching T Cells What to Attack
T cells cannot recognise free antigen — they can only respond to peptide fragments displayed on the surface of other cells by MHC molecules. This requirement, called MHC restriction, was established by Zinkernagel and Doherty in their Nobel Prize-winning experiments demonstrating that cytotoxic T cells from virus-infected mice would only kill virus-infected cells sharing the same MHC haplotype. The biological logic of MHC restriction is to focus T cell surveillance on cells of the body — monitoring their internal protein content (through MHC class I) and the extracellular/endosomal environment sampled by professional APCs (through MHC class II).
T Cell Activation, Differentiation, and Effector T Cell Subsets
T cell activation requires three distinct signals delivered simultaneously: Signal 1 is TCR engagement with the specific peptide-MHC complex on the antigen-presenting cell (antigen-specific); Signal 2 is co-stimulation through CD28 binding to B7 molecules (CD80/CD86) on the activated APC (non-specific quality control signal); and Signal 3 is the cytokine environment produced by the APC and surrounding innate immune cells (directing the type of T cell response generated). The requirement for all three signals prevents inappropriate T cell activation by self-antigens: cells presenting self-peptides typically lack co-stimulatory molecules, so self-peptide/MHC binding in the absence of CD28 signalling leads to T cell anergy rather than activation.
Th1 Cells — Intracellular Pathogen Defence
Differentiated by IL-12 and IFN-γ; express transcription factor T-bet; produce IFN-γ and TNF-α. Activate macrophages to kill intracellular pathogens (Mycobacterium, Listeria, Leishmania). Drive CD8+ CTL responses. Mediate delayed-type hypersensitivity. Protective against intracellular bacteria and some viruses; excessive Th1 responses contribute to inflammatory bowel disease and multiple sclerosis.
Th2 Cells — Anti-Parasitic and Allergic Responses
Differentiated by IL-4; express transcription factor GATA-3; produce IL-4, IL-5, IL-13. Stimulate B cell class switching to IgE and IgG1. Activate eosinophils (via IL-5) and mast cells. Drive anti-helminth immunity. Excessive Th2 responses cause allergic diseases (asthma, atopic dermatitis, allergic rhinitis) by directing mast cell sensitisation with IgE and eosinophil recruitment.
Th17 Cells — Extracellular Bacteria and Fungi
Differentiated by TGF-β + IL-6 + IL-23; express transcription factor RORγt; produce IL-17A, IL-17F, IL-22. Recruit neutrophils to mucosal surfaces; maintain epithelial barrier integrity. Critical for defence against extracellular bacteria (Klebsiella, Staphylococcus) and fungi (Candida). Excessive Th17 responses contribute to psoriasis, ankylosing spondylitis, rheumatoid arthritis, and Crohn’s disease — explaining why IL-17 and IL-23 blockade is therapeutically effective in these conditions.
Tfh Cells — Germinal Centre and B Cell Help
T follicular helper cells are specialised CD4+ T cells that migrate into B cell follicles in lymph nodes, express CXCR5 (directing them to follicles), PD-1, ICOS, and the transcription factor Bcl-6, and secrete IL-21 and IL-4. They are essential for germinal centre reactions — providing T cell help to antigen-specific B cells, driving somatic hypermutation and affinity maturation, and selecting high-affinity B cell clones for plasma cell and memory B cell differentiation. Without Tfh cells, B cells can produce only T-independent antibody responses of lower affinity and limited class-switching.
Regulatory T Cells (Tregs) — Peripheral Tolerance
FoxP3+ Tregs are CD4+ T cells that suppress immune responses rather than promoting them. Natural Tregs (nTregs) develop in the thymus; induced Tregs (iTregs) differentiate from conventional CD4+ T cells in the periphery in response to TGF-β and IL-2. They suppress other T cells through multiple mechanisms: direct cell-cell contact (CTLA-4 competes with CD28 for B7 ligands, starving effector T cells of co-stimulation); secretion of suppressive cytokines (IL-10, TGF-β); IL-2 consumption (competing with effector T cells for survival signals); and induction of tolerogenic APC behaviour. FoxP3 mutations cause the fatal autoimmune syndrome IPEX (Immune Polyendocrinopathy, Enteropathy, X-linked).
Cytotoxic T Lymphocytes (CTLs) — Killing Infected Cells
CD8+ CTLs recognise peptide-MHC class I complexes on target cells and kill them through two mechanisms: perforin/granzyme pathway — perforin forms pores in the target cell membrane, allowing granzyme B entry and caspase activation, triggering apoptosis; and Fas/FasL pathway — CTL-expressed FasL (CD95L) binds Fas (CD95) on target cells, activating the extrinsic apoptosis cascade. CTLs kill without destroying themselves and can sequentially kill multiple target cells. Essential for clearance of viral infections, intracellular bacteria, and tumour cells. Exhaustion (reduced function after chronic antigen stimulation) is a key mechanism of immune evasion in chronic viral infection and cancer.
Signals Required for T Cell Activation
Signal 1: TCR-pMHC binding (specificity). Signal 2: CD28-B7 co-stimulation (APC activation quality control). Signal 3: Cytokines directing differentiation into effector subset. All three simultaneously.
Clonal Expansion Factor
A single antigen-specific naive T cell can expand to ~1,000–10,000 effector cells within 7–10 days of activation, then contract to ~10 memory cells after pathogen clearance — a 100-fold contraction from the peak effector population.
Memory T Cell Longevity
Memory T cells (central memory TCM and effector memory TEM) persist for decades — providing the immunological basis for lifelong protection after childhood vaccination or infection, sustained by periodic antigen-independent homeostatic proliferation driven by IL-7 and IL-15.
B Cell Activation, Germinal Centres, and Antibody Diversity
B cell activation and the subsequent generation of high-affinity antibodies is one of the most elaborate biological processes known — involving antigen recognition, T cell help, migration into germinal centre structures, somatic hypermutation of antibody genes, selection by antigen, and differentiation into long-lived antibody-secreting plasma cells or memory B cells. The germinal centre reaction is the engine of antibody diversity and affinity maturation — the molecular process by which antibody binding to antigen improves progressively over the course of an immune response.
BCR Crosslinking and Initial B Cell Activation
Naive B cells express surface IgM and IgD as the B cell receptor complex (BCR: surface immunoglobulin plus Igα/Igβ signalling subunits). Antigen binding to the BCR cross-links multiple receptors, triggering the BCR signalling cascade: Src-family kinases (Lyn, Blk) phosphorylate ITAMs on Igα/Igβ, recruiting Syk which activates PLCγ2, generating IP₃ and DAG, leading to calcium signalling and PKC activation — ultimately activating NF-κB, NFAT, and AP-1 transcription factors. T-independent antigens (bacterial polysaccharides with repeating epitopes) can activate B cells through BCR crosslinking without T cell help, producing primarily IgM antibodies without somatic hypermutation or class switching. T-dependent antigens require Tfh cell help for full activation, germinal centre entry, and high-affinity IgG, IgA, or IgE production.
Germinal Centre Formation and Somatic Hypermutation
Activated B cells and their cognate Tfh cells enter B cell follicles in lymph nodes and spleen, forming germinal centres (GCs) — structures visible as pale oval zones in histological sections of lymphoid tissue. Within the GC dark zone, B cells proliferate rapidly (dividing every ~6–12 hours) and activation-induced cytidine deaminase (AID) introduces point mutations into the variable regions of the rearranged immunoglobulin genes at a rate ~10⁶-fold higher than the genomic background — a process called somatic hypermutation (SHM). SHM randomly mutates the antigen-binding residues, producing B cell variants with higher or lower antigen affinity than the parent cell.
Affinity Maturation — Selection of High-Affinity Variants
After hypermutating in the dark zone, GC B cells migrate to the light zone where they compete to bind antigen displayed on follicular dendritic cells (FDCs). B cells that have acquired mutations improving antigen affinity bind antigen better, internalise more peptide-MHC, and receive stronger Tfh signals (CD40L-CD40 and IL-21) — surviving to re-enter the dark zone for another round of hypermutation. B cells with decreased affinity fail to compete, receive insufficient Tfh help, and undergo apoptosis. This iterative cycle of mutation, migration, competition, and selection progressively enriches the GC population in high-affinity B cell variants — a molecular Darwinian process that can increase antigen-binding affinity by 100–1,000-fold over the course of a primary immune response.
Class Switch Recombination — Changing Antibody Effector Functions
Early B cell responses are dominated by IgM (from unswitched B cells). As the response matures, AID-mediated class switch recombination (CSR) changes the heavy chain constant region — and therefore the antibody class — while preserving the antigen-binding variable region. The switch is irreversible: deletional recombination removes the intervening DNA between the VDJ region and the new downstream constant region (e.g., Cγ1, Cγ2a, Cγ3, Cα, Cε). The class switched determines the effector function: IgG1/3 — complement and FcγR effectors; IgA — mucosal secretion; IgE — mast cell binding and Type I hypersensitivity. Cytokines from Tfh and the innate environment direct class switching: IL-4 → IgE; IL-10 + IL-21 → IgA; IFN-γ → IgG2a (mice) / IgG1 (humans).
Plasma Cell and Memory B Cell Differentiation
Successful GC B cells differentiate into one of two fates: long-lived plasma cells — terminally differentiated antibody-secreting cells that migrate to the bone marrow, are sustained by stromal survival signals (APRIL, BAFF, IL-6), and can produce antibody for decades without further antigen stimulation (the basis of long-lived serological protection); or memory B cells — quiescent, long-lived cells with high antigen-binding affinity that circulate and rapidly differentiate into plasma cells upon re-exposure to antigen. The division between plasma cell and memory B cell fate involves the transcription factors Blimp-1 (plasma cell fate) and Bach2/Pax5 (memory B cell fate).
Antibody Structure, Immunoglobulin Classes, and Effector Functions
Antibodies (immunoglobulins) are glycoproteins produced by plasma cells that bind antigens with exquisite specificity and trigger a range of effector mechanisms that eliminate the antigen. Their Y-shaped structure reflects two functional modules: the variable (Fab) regions that mediate antigen binding, and the constant (Fc) region that interacts with effector systems including Fc receptors on phagocytes and NK cells, and the C1q complement protein. The five immunoglobulin classes — IgG, IgM, IgA, IgD, and IgE — differ in their Fc regions and therefore in their effector functions, tissue distribution, and biological roles.
ANTIBODY BASIC STRUCTURE: 2 Heavy chains + 2 Light chains (κ or λ) Connected by disulfide bonds → Y-shaped tetramer Fab region (2×): antigen-binding; contains VH-CH1 + VL-CL Fc region (1×): effector functions; contains CH2-CH3 of heavy chains CDRs (3 per VH + 3 per VL = 6 total): hypervariable loops forming antigen contact surface IMMUNOGLOBULIN CLASSES: IgG (γ heavy chain) → 4 subclasses; most abundant serum Ig; crosses placenta; complement (G1,G3); opsonisation; ADCC IgM (μ heavy chain) → Pentamer in serum; first responder; best complement activator; monomer on naive B cell surface IgA (α heavy chain) → Dimer in secretions (sIgA); monomers in serum; mucosal immunity; breast milk; anti-complement IgE (ε heavy chain) → Very low serum; binds FcεRI on mast cells/basophils; allergy; anti-parasitic immunity IgD (δ heavy chain) → Naive B cell surface marker; very low serum; role in B cell activation; function largely unclear KEY EFFECTOR MECHANISMS OF ANTIBODIES: Neutralisation: block pathogen attachment to host cell receptors (anti-viral, anti-toxin) Opsonisation: Fc region recognised by FcγRs on phagocytes → enhanced phagocytosis Complement (CDC): IgM and IgG1/3 activate classical pathway → MAC lysis of pathogens ADCC: IgG Fc binds FcγRIII (CD16) on NK cells → NK cell killing of antibody-coated targets Mast cell activation:IgE cross-linking on FcεRI → degranulation (Type I hypersensitivity)
Antibody molecules secreted per plasma cell per second
A fully differentiated plasma cell in the bone marrow secretes approximately one million immunoglobulin molecules per second — making it one of the most productive protein-secreting cells in biology, with its rough endoplasmic reticulum and Golgi apparatus occupying virtually the entire cytoplasm in electron micrographs of mature plasma cells.
Cytokines: The Molecular Language of Immune Communication
Cytokines are small secreted proteins that mediate communication between immune cells — regulating the activation, differentiation, proliferation, and effector functions of both innate and adaptive immune cells. They act in autocrine (on the producing cell), paracrine (on adjacent cells), and endocrine (at distant sites) fashions, and their effects depend critically on which receptor is expressed by the responding cell. The cytokine network is characterised by redundancy (multiple cytokines sharing functions), pleiotropy (individual cytokines affecting multiple cell types), antagonism (cytokines opposing each other’s effects), and synergy (cytokines cooperating to produce effects greater than either alone).
| Cytokine / Family | Primary Source | Key Functions | Clinical / Therapeutic Relevance |
|---|---|---|---|
| IL-2 | Activated CD4+ T cells | T cell proliferation and survival (autocrine and paracrine); Treg maintenance; NK cell activation | IL-2 therapy (high-dose) for metastatic melanoma/renal cell carcinoma; engineered IL-2 variants (e.g., bempegaldesleukin) for tumour immunotherapy |
| IL-4 | Th2 cells, mast cells, basophils, ILC2 | B cell class switching to IgE/IgG1; Th2 differentiation; suppresses Th1; mast cell growth | IL-4Rα blockade (dupilumab) approved for atopic dermatitis, asthma, and CRS with nasal polyps — blocks both IL-4 and IL-13 signalling |
| IL-6 | Macrophages, Th17, fibroblasts, endothelium | Acute phase response (hepatic CRP, fibrinogen); Th17 differentiation (with TGF-β); B cell differentiation; fever | IL-6R blockade (tocilizumab, sarilumab) for rheumatoid arthritis and COVID-19 cytokine storm; elevated IL-6 as biomarker of inflammation |
| IL-12 | Macrophages, dendritic cells | Th1 differentiation; NK cell activation; IFN-γ induction; bridge between innate and adaptive immunity | IL-12/IL-23 p40 blockade (ustekinumab) for psoriasis and Crohn’s disease. IL-12 deficiency → susceptibility to mycobacteria |
| IL-17 | Th17 cells, ILC3, γδ T cells | Neutrophil recruitment; antimicrobial peptide induction in epithelium; mucosal barrier maintenance | IL-17A blockade (secukinumab, ixekizumab) highly effective in psoriasis and ankylosing spondylitis. IL-17RA mutations → susceptibility to mucocutaneous candidiasis |
| TNF-α | Macrophages, T cells, NK cells, mast cells | Inflammation; fever; cachexia; endothelial activation; granuloma formation; apoptosis (via TNFR1) | TNF blockade (infliximab, adalimumab, etanercept) — most widely used biologic class in RA, IBD, psoriasis, ankylosing spondylitis. Risk of reactivating latent TB |
| IFN-γ | Th1 cells, CD8+ T cells, NK cells | Macrophage activation (microbicidal); MHC class I and II upregulation; Th1 polarisation; antiviral state | IFN-γ therapy for chronic granulomatous disease. IFN-γ release assays (IGRA, QuantiFERON) diagnose latent TB. Deficiency → susceptibility to mycobacteria |
| Type I IFNs (IFN-α/β) | Virtually all cells (IFN-β); pDCs (IFN-α) | Antiviral state induction; MHC class I upregulation; NK cell activation; ISG induction; anti-proliferative | IFN-α therapy for hepatitis C (replaced by DAAs), hairy cell leukaemia, KS. Excessive type I IFN in SLE and Aicardi-Goutières syndrome |
| TGF-β | Tregs, macrophages, many cell types | Immunosuppression; Treg and Th17 differentiation (context-dependent); fibrosis; epithelial-mesenchymal transition | TGF-β drives fibrosis in many chronic diseases. Regulatory role in gut tolerance — IgA class switching in gut-associated lymphoid tissue. Target in cancer immunotherapy (immunosuppressive tumour microenvironment) |
| IL-10 | Tregs, macrophages (M2), Th2, Tfh | Anti-inflammatory; suppresses macrophage activation and Th1/Th17 responses; promotes B cell survival and IgA | IL-10 deficiency → severe inflammatory bowel disease in infants (IL-10Rα/Rβ mutations). IL-10 therapy explored for IBD but limited efficacy in trials |
Immune Tolerance and Autoimmunity: When Self-Recognition Fails
Immune tolerance — the specific non-responsiveness of the immune system to antigens — is the mechanism that prevents the devastating consequences of self-attack. Its failure produces autoimmune disease, affecting approximately 5–8% of the human population globally. Understanding the mechanisms of tolerance is the prerequisite for understanding the causes, immunopathology, and therapeutic targeting of autoimmune conditions.
Central Tolerance — Deletion in Primary Lymphoid Organs
In the thymus, developing T cells are tested for self-reactivity: cells that fail to interact with self-MHC die by neglect (positive selection eliminates ~95% of T cells that cannot be MHC-restricted); cells with high affinity for self-peptide/MHC undergo clonal deletion (negative selection) mediated by AIRE (Autoimmune Regulator) expression in thymic medullary epithelial cells — AIRE drives ectopic expression of peripheral tissue antigens in the thymus, ensuring T cells with high affinity for insulin, myelin, thyroglobulin, and other tissue antigens are deleted before reaching the periphery. AIRE mutations cause APS-1 (Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy), a multi-organ autoimmune syndrome demonstrating the non-redundant role of thymic central tolerance. B cell central tolerance in bone marrow deletes or edits BCRs that bind multivalent self-antigens.
Peripheral Tolerance — Silencing in Secondary Lymphoid Organs and Tissues
Many self-reactive lymphocytes escape central deletion — particularly those recognising antigens not expressed in the thymus, those with moderate (rather than high) self-affinity, and those with BCRs edited to reduced self-affinity. Peripheral tolerance suppresses these cells through: T cell anergy — antigen recognition without co-stimulation (as occurs when self-antigen is presented by resting tissue cells lacking B7 molecules) fails to activate the PI3K/Akt survival pathway, producing a functionally unresponsive state; active suppression by Tregs; deletion through Fas-FasL apoptosis in chronically stimulated autoreactive T cells; and immunological ignorance — where self-antigen concentration is too low to trigger activation. Failure of any of these mechanisms — from loss of Treg function to breakdown of tissue barriers releasing sequestered antigens — contributes to autoimmune disease initiation.
Molecular mimicry describes the hypothesis that T or B cells activated against a pathogen cross-react with self-antigens that share structural similarity with pathogen epitopes. The best-established clinical example is acute rheumatic fever — group A Streptococcus M protein contains epitopes that cross-react with cardiac myosin and the valvular endothelium, so the anti-streptococcal antibody response in susceptible individuals produces post-infectious cardiac valve damage (rheumatic heart disease). In Guillain-Barré syndrome, antibodies against Campylobacter jejuni lipo-oligosaccharides cross-react with gangliosides in peripheral nerve myelin, producing acute demyelinating neuropathy.
Molecular mimicry is not sufficient alone to explain autoimmune disease — most people with the same infection do not develop autoimmunity, indicating that genetic predisposition (particularly HLA type), microbiome composition, and bystander activation of self-reactive lymphocytes by the inflammatory environment also contribute. The viral hypothesis of type 1 diabetes and multiple sclerosis — that specific viral infections may trigger or accelerate autoimmunity in genetically susceptible individuals — remains under active investigation.
Hypersensitivity Reactions: The Gell and Coombs Classification
Hypersensitivity reactions are immunologically mediated tissue damage — the consequence of an immune response that is either appropriately targeted at a foreign antigen but disproportionately damaging (allergy, drug hypersensitivity), or directed against self-antigens (autoimmunity), or of inappropriate magnitude (immune complex disease). The Gell and Coombs classification system, developed in 1963, organises hypersensitivity reactions into four types based on the immunological mechanism responsible for tissue damage.
IgE-Mediated Hypersensitivity
Mechanism: Allergen cross-links IgE on sensitised mast cells/basophils → degranulation releasing histamine, prostaglandins, leukotrienes, tryptase. Onset within minutes.
Examples: Anaphylaxis (peanut, bee venom, penicillin), hay fever (rhinitis), allergic asthma, urticaria, atopic dermatitis, food allergy.
Treatment: Adrenaline (epinephrine) for anaphylaxis — the only life-saving treatment. Antihistamines, corticosteroids, allergen immunotherapy for chronic conditions. Anti-IgE (omalizumab) for severe asthma.
Antibody-Mediated Cell Destruction
Mechanism: IgG or IgM antibodies against cell-surface antigens activate complement (MAC lysis) or recruit phagocytes/NK cells (opsonisation, ADCC) to destroy the target cell. Onset hours to days.
Examples: Haemolytic disease of the newborn (anti-Rh IgG), ABO incompatible transfusion reactions, Goodpasture’s (anti-GBM), myasthenia gravis (anti-AChR), Graves’ disease (stimulatory anti-TSHR), immune thrombocytopenia.
Treatment: Remove offending antibody (plasmapheresis), immunosuppression, IVIG to block Fc receptors.
Immune Complex Deposition
Mechanism: Antigen-antibody complexes (IgG/IgM) deposit in vessel walls, glomeruli, or synovium when not efficiently cleared → complement activation, neutrophil recruitment, tissue damage. Onset hours to days post exposure.
Examples: SLE (anti-dsDNA complexes in kidney, joints, skin), serum sickness, post-streptococcal glomerulonephritis, Arthus reaction, hypersensitivity pneumonitis (farmer’s lung).
Treatment: NSAIDs/corticosteroids for acute immune complex disease; hydroxychloroquine, mycophenolate, cyclophosphamide for SLE.
T Cell-Mediated Hypersensitivity
Mechanism: Sensitised CD4+ Th1 or CD8+ T cells release cytokines and kill target cells upon re-exposure to antigen. No antibody involvement. Onset 48–72 hours (Td) or weeks (granulomatous).
Examples: Tuberculin skin test (PPD), contact dermatitis (poison ivy, nickel, latex), coeliac disease, type 1 diabetes (autoimmune β-cell destruction), allograft rejection, drug reactions (Stevens-Johnson).
Treatment: Topical/systemic corticosteroids, calcineurin inhibitors (tacrolimus), avoidance of trigger antigen.
Vaccines: Platforms, Mechanisms of Protection, and Immunological Principles
Vaccines are the most powerful application of immunological principles to human health — exploiting the adaptive immune system’s capacity for memory to provide protection against pathogens without the risks of natural infection. The history of vaccinology spans Edward Jenner’s 1796 cowpox inoculation against smallpox through Louis Pasteur’s attenuation methods to the mRNA vaccine platforms deployed against COVID-19 — a progression driven by increasing understanding of the molecular mechanisms of protective immunity.
Vaccine platform types — key immunological characteristics compared
mRNA Vaccines — A New Platform Built on Decades of Immunology
mRNA vaccines deliver synthetic mRNA encoding a viral antigen (the SARS-CoV-2 spike protein in COVID-19 vaccines) encapsulated in lipid nanoparticles (LNPs) that protect the mRNA from degradation and facilitate cellular uptake. Once inside muscle cells at the injection site, the mRNA is translated into protein using the cell’s own ribosomes. The expressed antigen — displayed on the cell surface (for membrane-anchored proteins) or secreted — is processed through both the MHC class I pathway (stimulating CD8+ T cell responses) and, through uptake by dendritic cells, the MHC class II pathway (stimulating CD4+ T cells and driving B cell help). The LNPs also activate innate immune sensing through endosomal TLRs and cytoplasmic nucleic acid sensors, providing a built-in adjuvant effect that promotes dendritic cell maturation and co-stimulatory molecule upregulation. This innate stimulation was a critical design challenge — the mRNA must be immunogenic enough to activate APCs but not so inflammatory as to cause significant local or systemic adverse effects, addressed through nucleoside modification (pseudouridine replacing uridine) that reduces innate sensing while maintaining translational efficiency. The technology’s speed advantage — the mRNA sequence can be updated in days once a new antigen sequence is identified — and the absence of live pathogen handling requirements represent significant platform advantages over traditional vaccine approaches.
Immunodeficiency: Primary Genetic Disorders and Secondary Causes
Immunodeficiency disorders result from the quantitative or qualitative deficiency of one or more immune system components — producing susceptibility to infections that would be readily cleared by an intact immune system. Primary immunodeficiencies (PIDs) are genetic — caused by mutations in genes encoding components of immune signalling, cell development, or effector mechanisms. Secondary immunodeficiencies arise from extrinsic causes — infection (HIV), malignancy, malnutrition, medications, or iatrogenic immunosuppression. The clinical presentation of immunodeficiency reflects which arm of immunity is deficient.
B Cell / Antibody Deficiencies
Susceptibility to extracellular bacteria (Streptococcus, Haemophilus) beginning after 6 months of age (when maternal IgG wanes). Examples: X-linked agammaglobulinaemia (XLA — BTK mutation, no mature B cells), CVID (Common Variable Immunodeficiency), selective IgA deficiency (most common PID). Treated with IVIG replacement.
T Cell Deficiencies
Susceptibility to intracellular pathogens (viruses, mycobacteria, fungi, Pneumocystis), opportunistic infections, and failure to thrive. Examples: DiGeorge syndrome (22q11.2 deletion, thymic hypoplasia), SCID (ADA deficiency, γc-chain deficiency, RAG1/2 defects). Combined T+B cell deficiencies are most severe.
Phagocyte Deficiencies
Susceptibility to catalase-positive bacteria (Staphylococcus aureus, Aspergillus) and fungi. Examples: Chronic granulomatous disease (CGD — NADPH oxidase mutations, impaired oxidative burst), LAD (Leukocyte Adhesion Deficiency — CD18/CD11b mutation, neutrophils cannot extravasate). CGD treated with IFN-γ and antifungal prophylaxis.
Immunology as a discipline connects directly to clinical practice across virtually every medical specialty — infectious disease (how pathogens evade immunity), oncology (tumour immunology and checkpoint inhibitor therapy), rheumatology (autoimmune disease mechanisms), transplantation (allograft rejection and tolerance induction), allergy (hypersensitivity mechanisms), paediatrics (primary immunodeficiency), and vaccinology. For students working on immunology assignments, clinical immunology case studies, infectious disease essays, or research papers in autoimmunity or vaccine immunology, our specialist team provides expert academic support. Visit our biology assignment help, nursing assignment help, and custom science writing services. For extended research projects and dissertations in clinical or experimental immunology, our dissertation support and research consultancy provide subject-specialist guidance at every academic level.
Expert Immunology and Health Sciences Academic Support
From immune cell mechanism essays and clinical immunology case studies to full immunology dissertations and vaccine research papers — specialist writers across all immunology disciplines and academic levels.
Frequently Asked Questions About Immunology
Further academic support: biology assignment help · nursing assignment help · science writing services · biology research papers · research paper writing · literature review help · dissertation support · public health help · nursing case studies · evidence-based practice papers · critical analysis papers · proofreading and editing · personalised academic assistance · challenging research topics · research consulting